Full Breakdown
New 15-Minute Test for Hepatitis C Enables Same-Day Treatment
12/12/2025, 10:28:12 PM
Rapid Diagnostic Breakthrough
Researchers at Northwestern University have developed a new rapid test for hepatitis C virus (HCV) that delivers results in just 15 minutes, significantly faster than existing options. This innovative test, which operates on the DASH (Diagnostic Analyzer for Specific Hybridization) platform, is designed to be used during a patient's clinical visit, allowing for immediate diagnosis and the initiation of treatment. The test has shown 100% agreement with results from commercial diagnostic platforms, as confirmed by independent evaluations from Johns Hopkins University.
Chronic hepatitis C affects approximately 50 million people globally and is responsible for around 242,000 deaths annually, primarily due to complications such as cirrhosis and liver cancer. Current diagnostic methods involve a two-step process: an initial antibody test followed by a PCR test to confirm active infection, often resulting in delays of several days or weeks for patients awaiting results. The new test aims to eliminate these delays, potentially preventing severe health complications and deaths associated with untreated infections.
Implications for Global Health
The introduction of this rapid test aligns with the World Health Organization's goal to eliminate hepatitis C by 2030. By facilitating same-day diagnosis and treatment, the test could significantly improve treatment uptake and compliance among patients, who often struggle with traditional diagnostic pathways. Dr. Claudia Hawkins, director of the Robert J. Havey, MD Institute for Global Health’s Center for Global Communicable and Emerging Infectious Diseases at Northwestern, emphasized the test's potential to revolutionize HCV care both in the United States and globally.
Official Statements & Responses
Dr. Sally McFall, co-director of the Center for Innovation in Global Health Technologies at Northwestern, noted, “We were able to develop a diagnostic test that can be performed at the point of care during a patient’s clinical visit, which could enable same-day diagnosis and treatment in support of HCV elimination efforts.” This sentiment was echoed by Dr. Hawkins, who stated, “By reducing delays and simplifying testing pathways, it has the potential to save millions of lives from the devastating liver-related complications of untreated HCV.”
Criticism & Opposition
While the new test presents significant advancements, some experts caution that widespread implementation will require addressing logistical challenges, including the availability of the DASH platform in resource-limited settings. Additionally, there may be concerns regarding the training of healthcare personnel to operate the new technology effectively.
Conflicting Reports & Gaps
The current landscape of hepatitis C diagnostics includes one FDA-approved rapid test that returns results in 40 to 60 minutes. However, the new DASH test's 15-minute turnaround time could render existing options less favorable. There is a need for further studies to assess the long-term impact of this new testing method on treatment outcomes and patient compliance.
What's Next
The findings regarding the new test were published in The Journal of Infectious Diseases on December 10, 2025. As healthcare systems consider integrating this rapid diagnostic tool, ongoing research and evaluation will be essential to ensure its effectiveness and accessibility in diverse clinical settings.
